Nxera Pharma Co., Ltd.
SOLTF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $579 | $85,720 | $79,671 | $87,078 |
| - Cash | $192 | $32,997 | $34,465 | $36,203 |
| + Debt | $427 | $64,723 | $66,264 | $67,900 |
| Enterprise Value | $814 | $117,446 | $111,470 | $118,775 |
| Revenue | $46 | $8,450 | $6,644 | $6,852 |
| % Growth | -99.5% | 27.2% | -3% | – |
| Gross Profit | $28 | $6,592 | $5,029 | $4,725 |
| % Margin | 60.4% | 78% | 75.7% | 69% |
| EBITDA | -$12 | $532 | -$1,111 | -$2,775 |
| % Margin | -26.7% | 6.3% | -16.7% | -40.5% |
| Net Income | -$11 | -$2,377 | -$760 | -$1,335 |
| % Margin | -24.8% | -28.1% | -11.4% | -19.5% |
| EPS Diluted | -0.12 | -26.35 | -8.45 | -14.86 |
| % Growth | 99.5% | -211.8% | 43.1% | – |
| Operating Cash Flow | -$20 | -$180 | $613 | -$10,970 |
| Capital Expenditures | -$1 | -$90 | -$109 | -$153 |
| Free Cash Flow | -$21 | -$270 | $504 | -$11,123 |